Cardiac Arrhythmia Network of Canada
14
2
4
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
1 terminated/withdrawn out of 14 trials
88.9%
+2.4% vs industry average
14%
2 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Reversal of Atrial Substrate to Prevent Atrial
Role: collaborator
Remote Patient Management of CIEDs
Role: collaborator
Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)
Role: collaborator
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
Role: collaborator
Remote Patient Management of CIEDs - Brady Devices
Role: collaborator
Antiarrhythmics or Ablation for Ventricular Tachycardia 2
Role: collaborator
COVID-19 Virtual Care at Home
Role: collaborator
Decreasing Hospital Admissions From the ED for AAFF
Role: collaborator
Atrial Fibrillation Trial to Evade Recurrence: effectS of Hiit Before electrO-Cardioversion for 3-weeKs
Role: collaborator
Virtual for Care Atrial Fibrillation Patients Using VIRTUES
Role: collaborator
Computer Simulated Atrial Fibrillation Tool
Role: collaborator
Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Role: collaborator
Remote Patient Management for Cardiac Implantable Electronic Devices
Role: collaborator
A.Fib Emergency Department Study Atrial Fibrillation
Role: collaborator
All 14 trials loaded